Diadenosine tetraphosphate (AP 4 A), an endogenous diadenosine polyphosphate, reduces ischemic injury in the heart. In this study, we report the potent and protective effects of AP 4 A in rodent models of stroke and Parkinson's disease. AP 4 A, given intracerebroventricularly before middle cerebral artery (MCA) ligation, reduced cerebral infarction size and enhanced locomotor activity in adult rats. The intravenous administration of AP 4 A also induced protection when given early after MCA ligation. AP 4 A suppressed terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL) induced by hypoxia/reperfusion in primary cortical cultures, and reduced both ischemia-induced translocation of mitochondrial cytochrome c and the increase in cytoplasmic caspase-3 activity in vivo. The purinergic P 2 /P 4 antagonist di-inosine pentaphosphate or P 1 -receptor antagonist sulfonylphenyl theophylline, but not the P 2 -receptor antagonist suramin, antagonized the effect of AP 4 A, suggesting that the observed protection is mediated through an antiapoptotic mechanism and the activation of P 1 -and P 4 -purinergic receptors.
Introduction
Diadenosine polyphosphates (AP n As) are a group of compounds that contain two adenosine moieties bridged by three to six phosphates. Diadenosine tetraphosphate (AP 4 A), a major representative of AP n As, has been found to be highly concentrated in tears (Pintor et al., 2002) , and it may be involved in extracellular and intracellular signaling in the brain (Oaknin et al., 2001; Emanuelli et al., 1998; Kisselev et al., 1998) . AP 4 A is stored in secretory granules with ATP and can be released after stimulation in a Ca 2ϩ -dependent manner (Pivorun and Nordone, 1996) and during insults or oxidative stress (Bochner et al., 1984) . AP 4 A interacts with purinergic P 1 - (Klishin et al., 1994) and P 2 - (Lazarowski et al., 1995) receptors. Recent studies have indicated that high-affinity binding sites for AP 4 A (Pintor et al., 1993) , as differentiated from P 1 -or P 2 -receptors, are found in the olfactory bulb, cerebral cortex, and striatum, as well as several other brain areas (Rodriguez-Pascual et al., 1997) . These receptors have been identified as purinergic P 4 -receptors (RodriguezPascual et al., 1997) . In the synaptic terminals of rat midbrain and cerebellum, the interaction of AP n As and P 4 receptors cannot be cross-desensitized by ATP . Taken together, these data suggest that AP 4 A may use unique signal transduction pathways and may activate physiological responses different from those caused by ATP or adenosine.
Previous studies have indicated that AP 4 A reduces ischemic injury in the heart (Ahmet et al., 2000; Khattab et al., 1998) . The role of AP 4 A in the CNS is not clear. AP 4 A can be released from the striatum after the systemic administration of amphetamine . ⑀-AP 4 A, an AP 4 A analog, has been found to decrease extracellular glutamate levels in the striatum (Oaknin et al., 2001) . We now report that AP 4 A has protective effects in the cortex and midbrain in defined rat models of stroke and Parkinson's disease, which have predictive value for therapeutic development.
Materials and Methods
In vitro primary neuronal cultures, hypoxia, and cell death. Cells were isolated at embryonic day 15 from timed-pregnant rats. Cells were plated in Neurobasal media containing B 27 supplement, 200 mM L-glutamine, and 25 M L-glutamate for 4 d. Cells were treated with AP 4 A (SigmaAldrich Chemical, St. Louis, MO) or vehicle and incubated for 18 hr in a hypoxic incubator (3% O 2 , 5% CO 2 ; Thermo Forma). After hypoxia, cells were returned to normoxia conditions (21%O 2 , 5% CO 2 ) for 24 hr. Media were collected and assayed for lactate dehydrogenase (LDH) activity (Cytotoxicity Detection Kit; Roche Products, Penzberg, Germany). Cultures were assayed for DNA fragmentation using a terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL)-based method (In Situ Cell Death Detection Kit; Roche) or activated caspase-3 activity (see below) using the ApoAlert kit (Clontech, Palo, Alto, CA).
Animals and drug administration for in vivo studies. Adult male Sprague Dawley rats were used for this study. For intraventricular administration of AP 4 A, animals were anesthetized with chloral hydrate (0.4 gm/kg, i.p.). AP 4 A (3 or 30 nmol/20 l) was administered through a Hamilton syringe over 10 min intracerebroventricularly. The coordinates were 0.8 mm posterior to the bregma, 1.5 mm lateral to the midline, and 3.5 mm below the dura surface. The speed of injection was controlled by a syringe pump at a rate of 2.5 l/min. A systemic injection of AP 4 A (10 mg/kg) or vehicle (saline, 1 ml) was given through the tail vein at 5-10 min after removal of the ligature on the right MCA (see below).
Brain ischemia/reperfusion. Anesthetized rats were subjected to cerebral ischemia. The ligation of the right middle cerebral artery (MCA) and bilateral common carotids (CCAs) was performed using methods described previously (Chen et al., 1986; Wang et al., 2001a) . The right MCA was ligated with 10 -0 suture. The ligature was removed after 60 min of ischemia to allow reperfusion. Body temperature was monitored with a thermistor probe and maintained at 37°C throughout the period of surgery and recovery.
Cerebral blood flow in stroke animals. Cortical blood flow was continuously measured using a laser Doppler flowmeter (PF-5010, Periflux system, SE) in anesthetized animals (Wang et al., 2001b) . A Doppler probe (0.45 mm in diameter) was stereotaxically placed in the right frontoparietal cortex (1.3 mm posterior, 2.8 mm lateral to the bregma and 1.0 mm below the dura).
Behavioral measurements in stroke animals. Animals were placed in an Accuscan activity monitor (Columbus, OH) 2 d after ischemia for behavioral recording (Wang et al., 2001a) . The monitor contained 16 horizontal and 8 vertical infrared sensors spaced 2.5 cm apart. The vertical sensors were situated 10.5 cm from the floor of the chamber. Motor activities, such as horizontal activity (total number of beam interruptions that occurred in the horizontal sensors), total distance traveled, number of horizontal or vertical movements, movement and rest time, were calculated by the number of beams broken by the animals from 0 to 30 min after being placed in the chamber.
Triphenyltetrazolium chloride staining in stroke animals. Two days after stroke, some animals were killed for triphenyltetrazolium chloride (TTC) staining (Wang et al., 2001a ). The brain tissue was then removed and sliced into 2.0 mm thick sections. The brain slices were incubated in a 2% TTC solution. The area of infarction on each brain slice was measured double blind using a digital scanner. The total infarction volume in each animal was obtained from the product of average slice thickness (2 mm) and the sum of the area of infarction in all brain slices.
Cytochrome c in stroke animals. Brain tissues from stroke rats were harvested at 8 hr after the onset of reperfusion for Western blot analysis of cytochrome c (Tsao and Su, 2001 ). The fourth 2 mm coronal section (6 -8 mm from rostral end) from each brain was dissected and homogenized in lysis buffer. We have demonstrated previously that this section contains the largest area of infarction (Chang et al., 2002) . The brain-tissue homogenates were centrifuged at 800 ϫ g for 20 min at 4°C. The resulting supernatant was additionally centrifuged at 10,000 ϫ g for 20 min at 4°C to obtain the heavy membrane pellet enriched for mitochondria. The supernatants were centrifuged again at 100,000 ϫ g for 60 min at 4°C. The resulting supernatant was used as the soluble cytosolic fraction. The mitochondrial pellet was dissolved in lysis buffer and centrifuged at 10,000 ϫ g for 20 min at 4°C to make soluble protein. Fifty micrograms of soluble protein samples from subcellular fractionations were separated by electrophoresis using 10 -12% SDS-PAGE gel. Gels were electrotransferred onto nitrocellulose membranes. The membranes were blocked for 1 hr in TBS/0.05% Tween 20 containing 5% nonfat dried milk and then probed with monoclonal mouse anti-cytochrome c antibody (BD PharMingen, San Diego, CA) at a 1:500 dilution at 4°C overnight. The amounts of mitochondria were normalized with a mitochondrial marker (voltagedependent anion channel, VDAC). Immunoblot analysis was performed by probing with horseradish peroxidase (HRP)-labeled secondary antibodies, developing with enhanced chemiluminescence (ECL) Western blotting detection reagents, and exposing to Hyperfilm-ECL (Amersham Biosciences, Arlington Heights, IL).
Caspase-3 enzymatic activity in stroke animals. Activated caspase-3 enzyme activity was measured using the ApoAlert kit (Clontech) (Wang et al., 2001a) . Eight hours after the onset of reperfusion, animals were killed and the brain tissue was removed. The fourth 2 mm coronal section from each brain was dissected and homogenized in lysis buffer for the same rationale noted previously. Caspase-3 activity was determined fluorometrically by the formation of 7-amino-4-trifluromethyl coumarin (AFC) from Asp-Glu-Val-Asp-7-amino-4-trifluoromethyl coumarin (DEVD-AFC). The selective caspase-3 inhibitor DEVD-aldehyde (DEVD-CHO) was included, at a concentration of 10 M, to ensure that the enzymatic reaction was specific.
6-OHDA lesioning and amphetamine-induced rotation. Rats were anes- thetized with chloral hydrate (0.4 gm/kg, i.p.) and were injected with 6-OHDA (9 g/4 l in normal saline containing 0.2 mg/ml ascorbic acid) over 4 min, into the left medial forebrain bundle [Ϫ4.4 mm anteroposterior (AP), 1.2 mm mediolateral relative to the bregma, and 7.8 mm below the dura]. One month after lesioning, the unilaterally 6-OHDA-lesioned rats were tested for rotational behavior in response to subcutaneous amphetamine injections (5 mg/kg) in an automated rotometer (Chiang et al., 2001) . TUNEL and tyrosine hydroxylase immunostaining in 6-OHDA-lesioned animals. The 6-OHDA-lesioned animals were killed at 48 hr for TUNEL (Zuch et al., 2000) . Some animals treated with 6-OHDA were killed 1 month after 6-OHDA lesioning for tyrosine hydroxylase (TH) immunostaining (Chiang et al., 2001) , respectively. The TUNEL assay was conducted according to the manufacturer's recommendations (In Situ Cell Death Detection Kit, Roche). Brains sections (30 m thick) were immunolabeled using an anti-tyrosine hydroxylase (TH) monoclonal, primary antibody (Boehringer Mannheim, Indianapolis, IN) and either a fluorescent Alexa 568 secondary antibody (Molecular Probes) or an HRP-conjugated secondary antibody (Jackson ImmunoResearch, West Grove, PA). Nuclei were counterstained with 4Ј,6-diamidino-2-phenylindole (Molecular Probes).
In vivo electrochemistry in 6-OHDA-lesioned animals. Six months after lesioning, some 6-OHDA-lesioned animals were anesthetized with urethane (1.25 gm/kg, i.p.). In vivo chronoamperometric measurements of extracellular dopamine (DA) concentration were performed as described previously (Zhou et al., 1996) . The recordings were taken at rates of 10 Hz continuously using Nafion-coated carbonfiber working electrodes (SF1A: Quanteon, Nicholasville, KY). The release of DA was measured by changes of extracellular DA concentration after the microinjection of KCl into the striatal parenchyma. KCl (70 mM) was applied locally through micropipettes. The working electrode and the micropipette were mounted together with sticky wax; tips were separated by 150 m. The electrode/pipette assembly was lowered into striatum (AP 1.0 mm, 2.5 mm lateral relative to the bregma and 4.0 -7.0 mm below the dura). Local application of KCl from the micropipettes was performed by pressure ejection using a pneumatic pump. The ejected volume was monitored by recording the change in the fluid meniscus in the pipette before and after ejection using a dissection microscope.
Blood pressure, heart rate, electrolytes, and blood CO 2 measurements. Physiological parameters were measured in 15 rats as described previously (Wang et al., 2001b) . Animals were anesthetized with chloral hydrate, and a polyethylene catheter was inserted into the right femoral artery. Mean arterial pressure was recorded through a strain gauge transducer and recorded on a strip chart recorder. Arterial blood (Ͻ1 ml) was withdrawn from the artery 30 min after the intracerebroventricular administration of AP 4 A (30 nmol) or vehicle. Blood gas, serum electrolytes and glucose were analyzed using standard methods.
Statistical analysis. Statistical analyses were performed with the t test, one-or two-way ANOVA, and the post hoc Newman-Keuls test. Significance was inferred at p Ͻ 0.05. Data are presented as means Ϯ SEM.
RESULTS Ischemia
AP 4 A-induced protection against hypoxia/re-oxygenation in vitro Primary neuronal cultures were treated with vehicle or AP 4 A (100 nM) followed by either hypoxia (3%O 2 for 18 hr)/re-oxygenation (21% O 2 for 24 hr) or normoxia (21%O 2 for 42 hr). AP 4 A itself did not alter LDH production or specific caspase-3 activity in a normoxic environment ( p Ͼ 0.05, t test). Nonspecific caspase-3 activity, defined as the activity found in the presence of the caspase-3 inhibitor DEVD-CHO (inhibitor) in the assay medium, was not detectable. Hypoxia/re-oxygenation enhanced LDH production (Fig. 1 A) and caspase-3 activity (Fig. 1 B) and elicited an increase in TUNEL (Fig. 1C,D) . All of these responses to hypoxia/re-oxygenation were significantly reduced by pretreatment with AP 4 A (Fig. 1 A-C) ( p Ͻ 0.05, one-way ANOVA) (Fig. 1 D,E) .
Pretreatment with AP 4 A increases locomotor activity and reduces infarction in stroke rats
Rats were pretreated with either vehicle (n ϭ 9) or AP 4 A (30 nmol, i.c.v.; n ϭ 10) 20 -30 min before middle cerebral artery occlusion. Animals were individually placed in activity chambers to measure their locomotor activity on the second day after stroke. Pretreatment with AP 4 A, compared with vehicle, significantly enhanced the horizontal activity, total distance traveled, number of horizontal or vertical movements, and movement time in stroke animals ( p Ͻ 0.05, t test) (Fig. 2D) .
One hour MCA ligation and 48 hr reperfusion resulted in clear-cut infarction of the cortex in animals pretreated with vehicle or AP 4 A, as examined by TTC staining (Fig. 2 A) . Infarction was additionally analyzed by two methods: (1) The volume of infarction, which equals 2 mm [thickness of the slice] ϫ [sum of the infarction area in all brain slices (mm 2 )]. (2) The area of the largest infarction in a slice from each rat. In 31 animals studied, pretreatment with AP 4 A (3 or 30 nmol, i.c.v.) dosedependently reduced the volume of infarction (Fig. 2 B) ( p Ͻ 0.05, F (2,28) ϭ 10.303, one-way ANOVA and Newman-Keuls test). Similarly, pretreatment with AP 4 A dose-dependently reduced the area of largest infarction in a given slice (Fig. 2C) ( p Ͻ 0.002, F (2,28) ϭ 8.410, one-way ANOVA; p Ͻ 0.05, post hoc NewmanKeuls test).
Parenteral treatment with AP 4 A after ischemia
The blood-brain barrier (BBB) can be transiently disrupted during ischemia, which provides a temporal window for the parenteral administration of AP 4 A to enter the brain. To test the hypothesis that the systemic administration of AP 4 A may reduce infarct volume, 17 adult rats were subjected to a 60 min right MCA ligation and treated at 5-10 min after removal of the ligature with an intravenous injection of either AP 4 A (10 mg/kg, n ϭ 8) or vehicle (n ϭ 9). Rats that had been treated with a systemic injection of AP 4 A had significantly higher locomotor activity than their respective controls ( Fig. 3D ; p Ͻ 0.05, t test). Most notably, the volume of infarct, determined at 48 hr after MCA occlusion, was significantly smaller in rats that had been treated with a systemic injection of AP 4 A early in the reperfusion period (Fig.  3A-C) ( p Ͻ 0.05, t test). These data demonstrate that AP 4 A, given intravenously in the early reperfusion period, exhibits a protective effect against ischemic injury.
Blood gas, electrolytes, and systemic blood pressure
We found that the intracerebroventricular administration of AP 4 A (30 nmol/20 l) did not acutely (25-30 min) alter systemic blood pressure, heart rate, or serum concentrations of glucose, electrolytes, and blood gases ( p Ͼ 0.05, t test) in 15 non-stroke animals (Fig. 4 A,B) .
Cerebral blood flow during stroke
Cerebral cortical blood flow was measured continuously using a fine (0.45 mm diameter) laser Doppler probe. Previous studies have indicated that this modified laser Doppler flowmetry can provide a high degree of spatial and temporal resolution (Wang et al., 2001a,b) . We found that cortical blood flow was significantly reduced to the same degree after MCA ligation in both vehicleand AP 4 A-treated animals (Fig. 4C1,C2 ) ( p ϭ 0.894, t test), suggesting that pretreatment of rats with AP 4 A did not alter cortical blood flow during ischemia.
Translocation of cytochrome c
In vehicle-treated animals (n ϭ 4), 60 min MCA occlusion and 8 hr reperfusion resulted in a significant decrease in the levels of cytochrome c protein in the mitochondria (Fig. 5A) . The intravenous injection of AP 4 A (n ϭ 3) in the early reperfusion period attenuated the reduction in mitochondrial levels of cytochrome c caused by cerebral ischemia and reperfusion ( p Ͻ 0.05, F (3,10) ϭ 357.168, one-way ANOVA and Newman-Keuls test). The ratio between cytochrome c levels in cytosol and that in mitochondria was significantly increased in the ischemic hemisphere in animals subjected to MCA occlusion and reperfusion, and treated with vehicle. This increase was attenuated by the administration of AP 4 A in the early reperfusion period. These data suggest that AP 4 A reduces the ischemia/reperfusioninduced translocation of cytochrome c from the mitochondria into the cytosol, which is thought to be a critical mechanism in apoptosis.
Caspase-3 activity at 8 hr after ischemia
Previous studies have indicated that the activity of caspase-3, a marker of apoptosis, is greatly increased as early as 8 hr after ischemia (Sasaki et al., 2000) . To investigate the effect of AP 4 A on caspase-3 activity, animals were subjected to 60 min MCA occlusion and 8 hr of reperfusion, and treated in the early reperfusion period with intravenous AP 4 A or vehicle. In vehicletreated control animals, MCA-occlusion and reperfusion resulted in a significant increase in the enzymatic activity of caspase-3 (Fig. 5B) . Compared with non-stroke animals, MCA occlusion increased caspase-3 activity 274.1 Ϯ 34.3% and 167.5 Ϯ 25.8% in the ipsilateral (ischemic side) and contralateral hemisphere, respectively ( p Ͻ 0.05, F (2,11) ϭ 43.514, one-way ANOVA and NewmanKeuls test). Caspase-3 enzymatic activity was significantly decreased in the brain sections obtained from animals treated with AP 4 A in the early reperfusion period ( p Ͻ 0.05, F (5,24) ϭ 90.736, one-way ANOVA and Newman-Keuls test) (Fig. 5B) .
P 1 -, P 2 -, and P 4 -receptor mediation
Numerous studies have indicated that adenosine has neuroprotective effects against ischemia. We also found that pretreatment with adenosine (30 nmol, i.c.v.) significantly reduced cerebral infarction in eight stroke rats (Fig. 6 A) ( p Ͻ 0.05, F (2,33) ϭ 17.095, one-way ANOVA and Newman-Keuls test). However, such protective effects of adenosine are much less than those of AP 4 A ( p Ͻ 0.05, one-way ANOVA) (Fig. 6 A) , suggesting that mechanisms other than adenosine signaling may be involved. To further characterize the interactions of AP 4 A with various purinergic P 1 -, P 2 , or P 4 -receptors, AP 4 A was co-administered with the selective P 1 -receptor antagonist sulfonylphenyl theophylline, the nonselective P 2 -receptor antagonist suramin, or the P 2 /P 4 -receptor antagonist di-inosine pentaphosphate (IP 5 I). We found that suramin (n ϭ 15) did not antagonize the reduction in total infarct volume caused by AP 4 A (Fig. 6 B) ( p Ͼ 0.05, F (2,22) ϭ 2.940, one-way ANOVA). Suramin (100 nmol) induced seizures in six of seven rats and was lethal in three. In contrast to suramin, AP 4 A-induced protection was significantly attenuated by IP 5 I (Fig. 6C) ( p Ͻ 0.05, F (2,26) ϭ 6.329, one-way ANOVA) or sulfonylphenyl theophylline (Fig 6 D) ( p Ͻ 0.05, F (2,23) ϭ 5.103, oneway ANOVA). These data suggest that activation of P 1 -and P 4 -, but not P 2 -, receptors, is involved in the observed neuroprotective effects of AP 4 A in the stroke rats.
6-OHDA lesioning
TUNEL in 6-OHDA-lesioned rats Six rats were pretreated intracerebroventricularly with AP 4 A or vehicle and lesioned unilaterally with 6-OHDA in the medial forebrain bundle. Animals were killed 2 d after 6-OHDA lesioning. An increase in TUNEL was found in the lesioned nigra in rats receiving vehicle pretreatment (Fig. 7A1,A2) . TUNEL was mainly colocalized with TH immunoreactivity in the nigral cells (Fig. 7A3) . AP 4 A pretreatment reduced the density of TUNEL (Fig. 7B1,B2 ).
Amphetamine-induced ipsilateral rotation in 6-OHDAlesioned rats
Amphetamine-induced rotation was evaluated 1 month after 6-OHDA lesioning in 31 rats. We found that control animals developed a marked ipsilateral rotation after injection (472 Ϯ 41 turns/hr). This response was significantly attenuated in animals pretreated with AP 4 A (93 Ϯ 29 turns/hr, p Ͻ 0.05, t test).
TH immunostaining in 6-OHDA-lesioned rats
Immunoreactivity to TH (Fig. 7C,D) was used to identify dopaminergic neurons and processes in 12 rats 1 month after lesioning. Very low TH immunoreactivity was noted in the striatum of 6-OHDA-lesioned rats, which had received vehicle (Fig. 7C ). There were minimal TH-positive neurons in the lesion-side nigra. In contrast, AP 4 A partially prevented the loss of TH immunoreactivity in the 6-OHDA-lesioned striatum and nigra (Fig. 7D) .
KCl-induced DA release in striatum
To determine whether the release of DA was preserved in animals treated with AP 4 A, 17 rats were used to detect dopamine release by in vivo chronoamperometry at 6 months after the injection of 6-OHDA. Of these, 10 rats (four pretreated with AP 4 A and six with saline) were lesioned with 6-OHDA, whereas seven rats, housed in the same environment, served as sham-operated controls. In the sham-operated rats, the local application of KCl resulted in a significant release of DA in the anterior striatum (Fig.  8 A,B) . In rats that had been lesioned with 6-OHDA, KCl caused only a very small release of DA (Fig. 8 A,B) . In contrast, the release of DA elicited by KCl in the striatum of rats treated with AP 4 A before the administration of 6-OHDA, was significantly greater ( p Ͻ 0.05, two-way ANOVA and Newman-Keuls test) (Fig. 8 B) . It should be noted that the peak release of DA in 6-OHDAlesioned rats treated with AP 4 A was significantly reduced compared with the sham-operated rats ( p Ͻ 0.05, two-way ANOVA and Newman-Keuls test) (Fig. 8 B) , suggesting that AP 4 A attenuates, but does not abolish, the reduction in the release of dopamine caused by 6-OHDA in the striatum.
Discussion
In this study, we have documented the efficacy of a novel and potent neuroprotective agent AP 4 A in rodent models of Parkinson's disease and stroke. Pretreatment with AP 4 A at 100 nM, a physiological concentration found in tears (Pintor et al., 2002) , reduced hypoxia/reoxygenation-induced increases in LDH in cortical cultures. Similarly, AP 4 A, given before MCA ligation attenuated cerebral infarction as well as the associated bradykinesia in a dose-related manner in stroke animals. These data suggest that AP 4 A has protective effects against hypoxic and ischemic injuries in the CNS. Because AP 4 A did not alter BP, blood gases, and blood electrolytes and did not alter cerebral blood flow during ischemia, the neuroprotective effect of AP 4 A in vivo is probably not indirectly mediated through the changes in systemic physiological parameters. We found that the application of AP 4 A even after an ischemic event reduced cerebral infarction and increased motor function. Such a protection may have clinical significance because treatment can be given after the occlusion in stroke patients. Interestingly, animals that received systemic AP 4 A, compared with intracerebroventricular AP 4 A, tended to recover better in one (number of horizontal movements in 30 Figure 5 . AP 4 A reduced both translocation of cytochrome c and caspase-3 activity in stroke brain. A, Mitochondrial cytochrome c protein levels were reduced in the ischemic (R) hemisphere of the vehicle-control animals. The intravenous administration of AP 4 A significantly increased the mitochondrial cytochrome c levels in the ischemic hemisphere compared with vehicle-treated animals. A representative Western blot showing the decrease in mitochondrial cytochrome c (top), but not mitochondrial marker VDAC (bottom), in the lesioned cortex is shown above the histogram. OD, Optical density. B, Increased caspase-3 enzymatic activity was reduced in the ischemic brains of AP 4 A-treated rats at 8 hr after stroke. Caspase-3 enzymatic activity was significantly increased in the ischemic (R) compared with the non-ischemic (L), hemisphere in vehicle-pretreated rats. The administration of AP 4 A in the early reperfusion period significantly reduced the ischemia-induced increase in caspase-3 activity. Specific caspase-3 activity, as examined by the addition of the caspase-3 inhibitor DEVD-CHO (inhibitor) in the assay medium, is shown above the dotted line. *p Ͻ 0.05. min, p ϭ 0.060, t test), but not all, of the locomotor behavioral test parameters. It is possible that the increased number of surgical procedures (or trauma) associated with intracerebroventricular injection may have caused less horizontal movement after stroke.
Pro-apoptotic mechanisms are activated during ischemia-reperfusion. For example, in ischemia or brain trauma, the translocation of cytochrome c from the mitochondria to the cytosol activates caspase-3 and facilitates apoptosis (Sasaki et al., 2000) . Prevention of apoptosis reduces brain damage (Kitagawa et al., 1998; Wang et al., 2001a,b) . In the current study, AP 4 A prevented both translocation of cytochrome c and activation of caspase-3 induced by ischemia/reperfusion. AP 4 A also reduced hypoxia/reoxygenation-induced TUNEL in cerebrocortical cells. Thus, our data support the view that the neuroprotective effects of AP 4 A involve the inhibition of several molecular steps that lead to the development of apoptotic cell death during ischemia-reperfusion of the brain.
Previous studies have indicated that AP 4 A increases intracellular calcium levels through P 2 receptors in cortical synaptic terminals and through suramin-insensitive dinucleotide P 4 receptors in the midbrain or cerebellum (Pintor et al., 1997) . Activation of P 4 receptors in rat midbrain synaptic terminals produces an initial voltageindependent calcium entry followed by a voltage-dependent increase in N-type calcium currents . These data suggest that AP 4 A exhibits differential functions in the cortex and midbrain through the purinergic receptors. In the present study, the neuroprotective effect of AP 4 A against ischemic injury was reduced by P 1 and P 2 /P 4 , but not P 2 , purinergic antagonists. Thus, it is likely that both P 1 -and P 4 -receptors are involved in AP 4 A-induced protection.
We have demonstrated that the protective effect of AP 4 A can be reproduced in other models of neuronal injury, in which neurons not located within the cortex are affected. The neurodegeneration induced by 6-OHDA in nigrostriatal dopaminergic neurons was reduced by pretreatment with AP 4 A. All of the effects of 6-OHDA, including motor bias, decrease in TH immunoreactivity in the substantia nigra and striatum, and attenuation of DA release in the striatum, were significantly reduced by pretreatment with AP 4 A. Because 6-OHDA can induce toxicity through the production of reactive oxygen species and apoptosis in nigral neurons (Zuch et al., 2000) and AP 4 A suppressed the 6-OHDAinduced increase in DNA fragmentation in nigra, we propose that AP 4 A partially attenuates the toxic effects of 6-OHDA, also through anti-apoptotic mechanism.
In conclusion, our results demonstrate that AP 4 A has neuroprotective effects against the injuries induced by ischemia in cortex and by 6-OHDA in nigrostriatal dopaminergic neurons. We propose that prevention of the activation of apoptosis by AP 4 A contributes importantly to the neuroprotective effects of this endogenous compound. These data may well be of clinical importance, insofar as systemic administration of AP 4 A after an ischemic episode may reduce reperfusion injury and improve outcome in patients with stroke. Figure 8 . AP 4 A elevated KCl-induced DA release in the 6-OHDA-lesioned striatum. A, In vivo chronoamperometric recordings demonstrate that the local application of 70 mM KCl (150 nl) to the anterior-dorsal striatum induced DA release in a non-lesioned rat (sham control). Lesioning the medial forebrain bundle abolished KCl-evoked DA release in an animal pretreated with vehicle. DA release was partially preserved by pretreatment with AP 4 A. Note that DA release in the 6-OHDA-lesioned rat receiving AP 4 A pretreatment has a lower amplitude but a longer half-life compared with that in a non-lesioned rat. B, DA release in the anterior striatum (4.0 -7.0 mm below the cortical surface, 2.5 mm lateral and 1.0 mm anterior to the bregma) was virtually abolished by 6-OHDA lesioning in four animals receiving vehicle pretreatment. Pretreatment with AP 4 A significantly enhanced DA release in 6-OHDA-lesioned rats ( p Ͻ 0.05, two-way ANOVA).
